期刊文献+

促性腺激素释放素拮抗剂联合人重组促黄体激素对卵巢功能减退患者妊娠结局的影响 被引量:4

The effect of recombinant human luteinizing hormone supplementation on IVF/ICSI outcome in women with ovarian hypofunction——aretrospective study in the GnRH antagonist protocol
下载PDF
导出
摘要 目的:研究重组人促黄体激素(r-hLH)在促性腺激素释放素(GnRH)拮抗剂促排卵方案中的应用指征。方法:回顾性分析2007年8月至2010年8月在本中心以GnRH拮抗剂方案促排卵的体外受精(IVF/ICSI)患者。卵巢功能减退纳入标准为卵泡刺激数(FSH)≥10U/L或窦卵泡数≤6个。研究分为两部分,第一部分纳入卵巢功能减退患者共107例,A组不添加r-hLH(n=80),B组添加r-hLH 75 U/d(n=27)。第二部分纳入应用GnRH拮抗剂+r-hLH+GnRH激动剂扳机的患者共71例并分为两组,C组为卵巢功能正常组(n=47),D组为卵巢功能减退组(n=24)。评价两组卵巢反应和妊娠结局的临床指标包括成熟卵子数、受精率、卵裂率、优质胚胎率、种植率和临床妊娠率。结果:①卵巢功能减退患者中,添加r-hLH组每优势卵泡平均雌激素水平、IVF成熟卵子数(100.00%vs 96.31%)显著高于对照组,种植率(29.41%vs 19.46%)和临床妊娠率(44.44%vs31.25%)均高于对照组,但差异无显著性。②添加了r-hLH的患者中,卵巢功能减退组IVF成熟卵子数(100.00%vs 93.71%)、IVF受精率(79.52%vs 38.46%)和ICSI受精率(84.85%vs 42.74%)显著高于卵巢功能正常组,种植率(28.89%vs 17.44%)、临床妊娠率(41.67%vs 25.53%)均高于卵巢功能正常组,但差异无显著性。结论:在GnRH拮抗剂方案中,添加r-hLH可以改善卵巢反应减退患者的卵巢反应和临床结局。卵巢功能正常者不是添加r-hLH的适应人群。 Objective: To study the indication of human recombinant luteinizing hormone(r-hLH) in GnRH antagonist protocol.Methods: Retrospective analysis.All the patients using GnRH antagonist protocol were enrolled in this study from Aug,2008 to Aug,2010.This study was divided into two parts.① The first part enrolled 107 patients with ovarian hypofunction(FSH≥10U/L or antral follicle count≤6),80 of them without supplementation of r-hLH(group A),27 of them received r-hLH together with GnRH antagonist(group B).② The second part enrolled 71 patients using r-hLH supplementation and GnRH agonist triggering,47 of them had normal ovary function(group C),and 24 of them had ovarian hypofunction(group D).The outcomes include mature oocytes rate,fertilization rate,cleavage rate,high-quality embryo rate,biomedical pregnancy rate,implantation rate and clinical pregnancy rate.Results: ① In group B,implantation rate(29.41% vs 19.46%) and clinical pregnancy rate(44.44% vs 31.25%) were higher than group A,but there were no statistical significance.IVF mature oocytes rate and E2/≥14mm follicle of group A was significantly higher than group B.② In group D,IVF mature oocytes rate(100.00% vs 93.71%),IVF fertilization rate(79.52% vs 38.46%) and ICSI fertilization rate(84.85% vs 42.74%) were significantly higher than group C.In group D,implantation rate(28.89% vs 17.44%) and clinical pregnancy rate(41.67% vs 25.53%) were higher than group C,but there were no statistical significance.Conclusions: Recombinant human luteinizing hormone supplementation to GnRH antagonist protocol can improve ovary response and pregnancy outcome of ovarian hypofunction women.There has no reason for women with normal ovary function to add r-LH in GnRH antagonist protocol.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第10期1425-1429,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金青年科学基金项目(30801236)资助
关键词 GNRH拮抗剂 促黄体激素 卵巢功能减退 体外受精 促排卵 GnRH antagonist luteinizing hormone ovarian hypofunction in vitro fertilization ovarian stimulation
  • 相关文献

参考文献19

  • 1Marrs R, Meldrum D, Muasher S,et al. Randomized trial to compare the effect of recombinant human FSH (fol- litropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment [J]. Reprod Biomed Online, 2008 (2) : 175-182.
  • 2Humaidan P,Bungum M,Bungum L,et al. Effects of recombinant LH supplementation in women undergoing as- sisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study [J]. Reprod Biomed Online,2004,8(6) :635-643.
  • 3Fabregues F,Creus M,Pernarrubia J,et al. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in downregulated women of advanced reproductive age [J]. Fertil Steril,2006,85(4) :925-931.
  • 4Nyboeandersen A, Humaidan P, Fried G,et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective,randomized,controlled trial [ J ]. Hum Reprod, 2008,23 ( 2 ) : 427-434.
  • 5Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, et al. Recombinant human LH supplementation during GnRH an- tagonist administration in IVF/ICSI cycles:a prospective randomized study [J]. Hum Reprod,2004,19 (9) : 1979- 1984.
  • 6Sauer MV,Thornton II MH,Schoolcraft W,et al. Comparative efficacy and safety of cetrorelix with or without mid- cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction[J]. Reprod Biomed Online, 2004,9 (5) : 487-493.
  • 7Griesinger G, Schuhze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recom- binant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol [ J ]. Hum Reprod, 2005,20 (5) : 1200-1206.
  • 8Levi-Setti PE, Cavagna M,Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrore- lix) in ovarian stimulation for ICSI:comparison of r-FSH alone and in combination with r-LH [J]. Eur J Obstet Gynecol Reprod Biol,2006,126(5) :212-216.
  • 9Bosch E,Labarta E,Crespo J,et al. Impact of luteinizing hormone administration on gonadotropin-releasing hor- mone antagonist cycles:an age-adjusted analysis[J]. Fertil Steril,2011,95 (3) : 1031-1036.
  • 10Baruffi RL,Mauri AL,Petersen CG,et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protoco1:a metaanalysis[J]. Reprod Biomed Online, 2007,14(1 ) : 14-25.

同被引文献71

  • 1林仙华,叶碧绿,赵军招,黄学锋.基础FSH/LH比值对预测年轻不孕患者IVF-ET周期卵巢反应性的影响[J].现代妇产科进展,2006,15(12):930-933. 被引量:52
  • 2Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod, 2002, 17(4): 874-85.
  • 3Kolibianakis EM. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A sys- tematic review and meta-analysis. Hum Reprod Update, 2006, 12(6):651-71.
  • 4Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadot- rophin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 20l 1, 11(5): CD001750.
  • 5Griesinger G, Kolibianakis EM, Papanikolaou EG, et al. Triggering of final oocyte maturation with gonadotropin- releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril, 2007, 88(3):616-21.
  • 6Alviggi C, Clarizia R. Who needs LH in ovarian stimulation? Reprod Biomed Online, 2006, 12(5):599-607.
  • 7Filicori M, Cognigni GE. Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovu- lation induction. J Clin Endocrinol Metab, 2001, 86(4): 1437- 41.
  • 8Herr F, Liang OD, Herrero J, et al. Possible angiogenic roles of insulin-like growth factor II and its receptors in uterine vascular adaptation to pregnancy. J Clin Endocrinol Metab, 2003, 88(10):4811-7.
  • 9Licht P, Russu V, Lehmeyer S, et al. Cycle dependency of intrauterine vascular endothelial growth factor levels is cor- related with decidualization and corpus luteum function. Ferfil Steril, 2003, 80(5): 1228-33.
  • 10Filicori M, Fazleabas AT, Huhtaniemi I. Novel concepts of human chorionic gonadotropin: reproductive system inter- actions and potential in the management of infertility. Fertil Steril, 2005, 84(2):275-84.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部